Labcorp Holdings (NYSE:LH) reported first-quarter earnings this morning that topped analyst expectations on both the top and bottom lines, sending shares higher in premarket trading. The diagnostic and laboratory services giant also raised its full-year guidance, signaling confidence in its operational momentum heading into the rest of 2026.
Earnings Beat and Revenue Results
For the quarter ended March 31, 2026, Labcorp reported revenue of $3.54 billion, a 5.8% increase from $3.35 billion in the same period last year. While this figure came in slightly below the analyst consensus estimate of $3.61 billion, the company delivered a stronger-than-expected bottom line.
Non-GAAP diluted earnings per share came in at $4.25, surpassing the analyst consensus of $4.22. On a GAAP basis, diluted EPS landed at $3.35, compared to $2.52 in the prior-year quarter — a 32.9% jump. The earnings beat was driven by improved operational efficiencies and higher margins across both of Labcorp's major segments.
Segment Performance and Key Drivers
Labcorp operates through two primary segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS).
- Diagnostics Laboratories (Dx): This segment, which covers routine and specialty testing, benefited from increased patient volumes and a favorable test mix. The company has been expanding its footprint in high-growth specialty areas, including oncology, neurology, and autoimmune disease testing. Revenue growth in Dx was supported by Labcorp's extensive network of patient service centers and rapid response laboratories.
- Biopharma Laboratory Services (BLS): The BLS segment provides drug development and companion diagnostic solutions. This division continued to see steady demand from pharmaceutical and biotech clients, particularly in early-stage research and clinical development. The segment also includes crop protection and chemical testing services, which added to overall stability.
Outlook and Full-Year Guidance Raised
Management raised its full-year 2026 guidance, reflecting increased confidence in the company's trajectory. The updated outlook compares favorably to current sell-side estimates. Analysts currently project full-year 2026 revenue of $15.11 billion and non-GAAP EPS of $18.32. Labcorp's raised guidance suggests the company expects continued operational strength through the rest of the year.
For the second quarter of 2026, analysts are modeling revenue of approximately $3.81 billion and EPS of $4.91. The company's positive start to the year and upward revision to annual targets could position it to meet or exceed these near-term expectations.
Market Reaction
Despite a slight revenue miss versus consensus, the stronger-than-expected EPS and the upgraded full-year outlook drove a positive response in the market. Labcorp shares were trading approximately 1.6% higher in premarket action as of this writing.
This positive move comes after a somewhat disappointing recent stretch. Over the past week, the stock has declined by about 5.7%, and over the past month, it has fallen roughly 3.6%. The earnings report and the raised guidance appear to be providing a much-needed catalyst for a reversal.
Analyst Views
The earnings beat and raised guidance are likely to reinforce a constructive view among sell-side analysts covering Labcorp. Key areas of focus for analysts include:
- Margin expansion: The significant improvement in diluted EPS, outpacing revenue growth, indicates that cost controls and operational leverage are working in Labcorp's favor.
- Specialty testing growth: Continued investment in high-margin specialty areas like oncology and neurology is expected to drive long-term profitability and differentiate Labcorp from peers.
- Biopharma pipeline: The stability in the BLS segment, supported by long-term drug development contracts, adds a layer of visibility to future earnings.
Where to Find More Data
For a deeper look at Labcorp's historical earnings performance and future projections, including detailed analyst estimates and forecasts, visit:
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research or consult with a licensed financial professional before making investment decisions.